Atreca
researches, discovers, develops and commercializes novel immunotherapies for the treatment of cancer... Read moreAtreca
researches, discovers, develops and commercializes novel immunotherapies for the treatment of cancer... Read more
News
May 20, 2024
Business Wire
Press Release: Atreca : Immunome Announces Completion of Purchase of Assets from Atreca
Mar 11, 2024
MarketScreener
Atreca: Atreca : Failure to Satisfy Listing Rule - Form 8-K
Jan 02, 2024
Citybizlist
Atreca: Immunome to Acquire Antibody-Related Assets and Materials from Atreca
Dec 26, 2023
MarketScreener
Atreca: BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
Nov 15, 2023
Post Online Media
Atreca: Atreca loss $36.2 million, will cut 40% of jobs
Nov 15, 2023
Pharamceutical Technology
Atreca: Atreca downsizes again to focus on antibody-drug conjugate programmes
Nov 14, 2023
MarketScreener
Atreca: Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
Sep 28, 2023
The Real Deal
Atreca: Atreca to exit HQ at Alexandria life science campus in San Carlos
Sep 28, 2023
Commercial Observer
Atreca: Alexandria Says It's Already Backfilling Atreca's Nixed Lab Lease In Silicon Valley
Aug 18, 2023
Americanbankingnews
Atreca: Atreca, Inc. (NASDAQ:BCEL) to Post Q3 2023 Earnings of ($0.36) Per Share, Wedbush Forecasts
Atreca Competitors
1
2
3
4
5
6
7
8
9
10